| Identification | Back Directory | [Name]
NU 2058 | [CAS]
161058-83-9 | [Synonyms]
CS-2601
NU2058>
2-aMino-6-purine
NU 2058;NU-2058;NU2058
O-Cyclohexylmethylguanine
2-Amino-6-(cyclohexylmethoxy)purine
NU-2058;O6-(CYCLOHEXYLMETHYL)GUANINE
6-(Cyclohexylmethoxy)-9H-purin-2-amine
2-aMino-6-[(cyclohexylMethyl)oxy]purine
9H-Purin-2-amine, 6-(cyclohexylmethoxy)- | [Molecular Formula]
C12H17N5O | [MDL Number]
MFCD05664734 | [MOL File]
161058-83-9.mol | [Molecular Weight]
247.3 |
| Chemical Properties | Back Directory | [Melting point ]
199°C(lit.) | [Boiling point ]
424.8±55.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
DMSO: 22 mg/mL
| [form ]
powder to crystal | [pka]
7.36±0.20(Predicted) | [color ]
white
| [λmax]
281nm(MeOH)(lit.) | [InChI]
InChI=1S/C12H17N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h7-8H,1-6H2,(H3,13,14,15,16,17) | [InChIKey]
MWGXGTJJAOZBNW-UHFFFAOYSA-N | [SMILES]
N1C2C(=NC(N)=NC=2OCC2CCCCC2)NC=1 |
| Hazard Information | Back Directory | [Description]
NU 2058 is an inhibitor of cyclin-dependent kinase 1 (Cdk1) and Cdk2 (IC50s = 7.0 and 17 μM, respectively). Increased Cdk activity is often associated with human tumors, and inhibitors of Cdks, including NU 2058, can arrest cell cycling in cancer cells in vitro. | [Uses]
Competitive inhibitor of CDK1/cyclin B (IC50=5μM) and CDK2/cyclin A (IC50=12μM). Pharmacologically distinct from the relative specific inhibitor of CDK1/2 roscovitine . | [Biological Activity]
Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (K i values are 5 and 12 μ M respectively). Inhibits growth of human tumor cells in vitro (mean GI 50 = 13 μ M). Also inhibits DNA topoisomerase II ATPase activity (IC 50 = 300 μ M). | [IC 50]
CDK1: 26 μM (IC50); CDK2: 17 μM (IC50); CDK2: 12 μM (Ki) | [storage]
Store at +4°C | [References]
[1] IAN R. HARDCASTLE. N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2[J]. Journal of Medicinal Chemistry, 2004, 47 15: 3710-3722. DOI: 10.1021/jm0311442
[2] ROGER J. GRIFFIN et al. et al. Structure-Based Design of 2 -Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine Inhibitors of Cyclin-Dependent Kinases 1 and 2.[J]. ChemInform, 2003, 34 51. DOI: 10.1002/chin.200351143
[3] N JOHNSON. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells[J]. British Journal of Cancer, 2009, 102 2: 342-350. DOI: 10.1038/sj.bjc.6605479
[4] A C RIGAS N J C C N Robson. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer[J]. Oncogene, 2007, 26 55: 7611-7619. DOI: 10.1038/sj.onc.1210586 |
|
|